ONE DESIGN CENTER PLACE, BOSTON, MA
Investor Presentation
Reports First Quarter 2026 Financial Results
Annual Report to Security Holders
Reports Fourth Quarter and Full Year 2025 Financial Results
Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases
Reports Third Quarter 2025 Financial Results
Reports Second Quarter 2025 Financial Results
Shareholder votes
Q1
FY 2024
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence